References
- Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluo-rouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet 2000; 355: 1041–1047.
- Elfring G, Emanuel D, Rostagi R, et al. Patterns of use and mortality in the community oncology practice setting among patients receiving first-line weekly bolus irinotecan/5-fluorouracil/leucovorin (IFL) for metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 2002; 16: (abstr 530).
- Goldberg RM, Morton RF, Sargent DJ, et al. N9741: oxaliplatin (Oxal) or CPT-11 + 5-fluorouracil (5FU)/leucovorin (LV) or oxal + CPT-11 in advanced colorectal cancer (CRC). Proc Am Soc Clin Oncol 2003; 22: (abstr 1009).
- Miller L, Emanuel D, Elfring G, et al. 60-day, all-cause mortality with first-line irinotecan/fluorouracil/leucovorin (IFL) or fluorouracil/leucovorin (FL) for metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 2002; 16: (abstr 515).
- Kusunoki M, Yanagi H, Kotera H, et al. Effects of phar-macokinetic modulating chemotherapy using oral UFT and continuous venous 5FU infusion on the prognosis of irradiated rectal carcinomas with p53 overexpression. Int J Oncol 1998; 13: 653–657.
- Takechi T, Uchida J, Fujioka A, et al. Enhancing 5-fluo-rouracil cytoxicity by inhibiting dihidropyrimidine dehydroge-nase activity with uracil in human tumor cells. Int J Oncol 1997; 11: 1041-1044.
- Ho DH, Pazdur R, Covington W, et al. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continu-ous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahy-drofuryl)-5-fluorouracil. Clin Cancer Res 1998; 4: 2085-2088.
- Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluo-rouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000; 343: 905–914.
- Goldberg RM, Sargent DJ, Morton RF, et al. A ran-domized controlled trial of fluorouracil plus leucovorin, irinote-can, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23–30.
- Tournigand C, Andre T, Achille E, et al. FOLFIRI fol-lowed by FOLFOX6 or the reverse sequence in advanced col-orectal cancer. J Clin Oncol 2004; 22: 229–237.
- Price T, Hill M. UFT/leucovorin plus irinotecan in advanced or metastatic colorectal cancer. Oncology 2000; 14: 28–31.
- Alonso V, Escudero P, Zorrilla M, et al. Phase I trial of weekly irinotecan combined with UFT as second-line treat-ment for advanced colorectal cancer. Eur J Cancer 2001; 37: 2385–2391.
- Alliot C. UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer. Br J Cancer 2004; 91: 599–600.